A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects

Tbo-filgrastim is a recombinant human granulocyte colony-stimulating factor approved by the US Food and Drug Administration to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incid...

Descripción completa

Detalles Bibliográficos
Autores principales: Adar, Liat, Avisar, Noa, Lammerich, Andreas, Kleiman, Robert B, Spiegelstein, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440426/
https://www.ncbi.nlm.nih.gov/pubmed/26028962
http://dx.doi.org/10.2147/DDDT.S81799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440426/
https://www.ncbi.nlm.nih.gov/pubmed/26028962
http://dx.doi.org/10.2147/DDDT.S81799

Ejemplares similares